Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy

NCT01111461 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01111461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01111461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2010
Completion date
October 31, 2015
Enrollment
133 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer